Norman Swan

So let's just start, Louisa, by talking because what we're doing here is talking about really comprehensive data from general practice, which hitherto has not really been available and it's linked to hospital data and very few other states in Australia have it other than New South Wales.

And you've been looking at, well, you literally were looking at semaglutide, but you've been looking at other GLP-1s as well.

And the beauty of this is it observes general practice behaviour, whether it's in the public sector or the private sector, and if you like, whether they're giving a script

on the PBS or a script or a private script, which for obesity is what they have to give.

And on the PBS or private, what was the balance between the two?

In other words, what was the balance for obesity versus diabetes?

Now, the advantage in Lumos data, as far as I understand it, is that for the first time in Australia, it links what happens in general practice to what happens in hospitals.

So you can track people from general practice to hospitals and back again.

And as I say, you can't do this in any other state.

One of the big cells for GLP-1s is that even just for obesity is that it prevents heart attacks, strokes and exacerbations of your diabetes and so on.

Are you seeing in this population fewer hospital admissions?

Now, when you did this study, semaglutide, brand name Ozempic, was the only game in town.

Since then, Ozempic has transformed for weight loss into Wegovi, a higher dose version of semaglutide.

And then Eli Lilly's come in with their terzepatide, known as Zepbound, or what's the other thing for Zepbound?

Monjaro.

Thank you very much for keeping me right here, yes.

You need real doctors here, Louisa.

That's the secret here.

What's happened since now that you've got more competition in the marketplace?

And what we should take away from that, just simply competition in the marketplace?